Close Menu

NEW YORK – X4 Pharmaceuticals has initiated a early-phase safety study of mavorixafor and ibrutinib (AbbVie's Imbruvica) for patients with CXCR4-mutated Waldenström’s macroglobulinemia (WM), a rare type of non-Hodgkin's lymphoma.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.